LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.45 2.37

Resumen

Variación precio

24h

Actual

Mínimo

3.36

Máximo

3.49

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+18.34% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

162M

1.2B

Apertura anterior

1.08

Cierre anterior

3.45

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2025, 17:29 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dic 2025, 16:21 UTC

Ganancias

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dic 2025, 16:18 UTC

Ganancias

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dic 2025, 23:53 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dic 2025, 22:48 UTC

Ganancias

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dic 2025, 22:12 UTC

Charlas de Mercado

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dic 2025, 22:03 UTC

Charlas de Mercado

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dic 2025, 21:56 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 21:44 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:38 UTC

Charlas de Mercado

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dic 2025, 21:19 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 20:06 UTC

Charlas de Mercado

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dic 2025, 19:55 UTC

Charlas de Mercado

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dic 2025, 19:24 UTC

Charlas de Mercado

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dic 2025, 19:06 UTC

Charlas de Mercado

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dic 2025, 18:27 UTC

Adquisiciones, fusiones, absorciones

Kraken to Acquire Backed Finance AG

2 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 17:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 15:17 UTC

Charlas de Mercado

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dic 2025, 14:47 UTC

Charlas de Mercado

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dic 2025, 14:38 UTC

Charlas de Mercado

Silver Steps Back From Record Levels -- Market Talk

2 dic 2025, 14:31 UTC

Charlas de Mercado
Ganancias

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

18.34% repunte

Estimación a 12 meses

Media 4 USD  18.34%

Máximo 4 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat